Optimization of Indazole-Based GSK-3 Inhibitors with Mitigated hERG Issue and Activity in a Mood Disorder Model.

Bipolar disorders still represent a global unmet medical need and pose a requirement for novel effective treatments. In this respect, glycogen synthase kinase 3β (GSK-3β) aberrant activity has been linked to the pathophysiology of several disease conditions, including mood disorders. Therefore, the development of GSK-3β inhibitors with good efficacy and safety profile associated with high brain exposure is required.

Discovery of Novel Imidazopyridine GSK-3β Inhibitors Supported by Computational Approaches.

The interest of research groups and pharmaceutical companies to discover novel GSK-3β inhibitors has increased over the years considering the involvement of this enzyme in many pathophysiological processes and diseases. Along this line, we recently reported on 1H-indazole-3-carboxamide (INDZ) derivatives -, showing good GSK-3β inhibition activity. However, they suffered from generally poor central nervous system (CNS) permeability.

Total synthesis of anthocyanidins via Heck reaction.

Anthocyanidin moiety was obtained by cyclization of a 2-hydroxychalcone prepared by the Heck approach to the synthesis of flavonoids. 1-(3,4-dimethoxyphenyl)-prop-2-en-1-one has been used as a coupling partner along with o-acetoxyiodobenzene in the Heck reaction.